Select Vendors Based on Evidence
Evaluate capability, experience, quality systems, regulatory history, resources, systems and operational controls before assigning critical GxP responsibilities.
Independent qualification, risk assessment and ongoing quality oversight for CROs, laboratories, manufacturers, clinical vendors, technology providers, pharmacovigilance partners and other critical GxP service providers.
Vendor qualification and oversight should demonstrate that third parties are capable of performing delegated activities, that responsibilities are clearly defined and that performance remains controlled after contracting and onboarding.
Evaluate capability, experience, quality systems, regulatory history, resources, systems and operational controls before assigning critical GxP responsibilities.
Align contracts, quality agreements, responsibility matrices, communication pathways and escalation requirements.
Use metrics, governance meetings, audits, quality signals and periodic review to detect declining performance and emerging risk.
Vendor governance becomes ineffective when qualification is treated as a one-time administrative task and ongoing oversight is based primarily on commercial performance rather than quality and compliance risk.
Critical and noncritical vendors follow the same questionnaire-based process without sufficient review of systems, data, operations or regulatory exposure.
Contracts and quality agreements do not clearly define ownership, notifications, approvals, records, escalation or oversight evidence.
Service-level metrics focus on timelines and cost but do not measure deviations, recurring errors, data quality, CAPA or compliance performance.
Significant changes, recurring quality issues, inspections or ownership transitions do not trigger formal reassessment.
The engagement can support the qualification of one critical provider, remediation of an existing vendor relationship or development of an enterprise vendor-governance program.
Development of a consistent method for determining vendor criticality and the appropriate depth of qualification and oversight.
Independent review of vendor capability, quality systems, regulatory history, operating model, systems and readiness to perform the proposed services.
Risk-based audits evaluating whether the service provider’s systems, controls and practices are suitable for the delegated GxP activity.
Development or remediation of agreements defining quality, compliance, communication and oversight responsibilities between the organization and vendor.
Design and implementation of performance review, quality metrics, governance meetings, escalation and documented oversight decisions.
Periodic and trigger-based reassessment, remediation oversight and controlled transition when vendor performance or risk is no longer acceptable.
Assessment scope is adapted to the vendor’s activities, data access, regulatory impact, operational dependency and the responsibilities delegated by the regulated organization.
Vendor governance should remain active throughout the commercial and operational relationship, not end when the initial qualification is approved.
Determine vendor criticality, potential GxP impact and the required qualification pathway.
Evaluate capability, quality systems, experience, regulatory history and operational suitability.
Establish approval conditions, written responsibilities, quality agreements and onboarding requirements.
Monitor quality indicators, service performance, changes, deviations, CAPAs and emerging risk.
Reassess continued suitability or control transfer, records and responsibilities during termination.
The engagement combines documentation review, stakeholder interviews, risk assessment, vendor evaluation and practical governance design.
Define the services, delegated responsibilities, systems, data, records, locations, subcontractors and intended operating model.
Determine potential impact on participants, patients, product quality, data reliability, continuity and regulatory compliance.
Review questionnaires, procedures, inspection history, audit evidence, organization, competence and quality-system maturity.
Conduct targeted audit activities where risk or available evidence requires deeper verification.
Define approval conditions, agreements, governance meetings, metrics, escalation thresholds and review frequency.
Evaluate performance, quality signals, significant changes, CAPAs, audits and continued suitability.
Deliverables are tailored to the vendor type, service criticality, regulatory environment and maturity of the existing oversight program.
Support can be delivered before selecting a new provider, during active service delivery or urgently when performance and compliance concerns threaten continuity or regulatory confidence.
A CRO, laboratory, manufacturer or technology provider requires qualification before onboarding.
Recurring deviations, delays, data issues or weak CAPAs indicate increasing quality risk.
Regulators or auditors identify insufficient qualification, agreements, monitoring or sponsor oversight.
The organization’s existing vendor program no longer supports the number or complexity of external partners.
Critical responsibilities and escalation requirements are not formally or clearly allocated.
Changes in ownership, systems, locations or operating model require reassessment.
Services, systems, records or data are moving to a replacement provider and require controlled transfer.
Periodic vendor reviews are overdue or unsupported by sufficient performance evidence.
A mature vendor-governance program supports informed provider selection, clearer accountability and earlier intervention when performance begins to threaten quality or compliance.
Select providers using evidence of capability, control, experience and suitability for the delegated GxP activity.
Use metrics, audits, governance and quality signals to identify declining performance before it becomes systemic.
Maintain documented responsibility, challenge, escalation and oversight evidence across outsourced activities.
Common questions from quality, clinical, manufacturing, laboratory, safety, IT, procurement and operational teams managing GxP vendors.
Yes. Qualification can include risk classification, questionnaire and document review, regulatory-history assessment, interviews, audit and a formal approval recommendation.
Not necessarily. The depth of qualification should be proportionate to the service, criticality, available evidence, data access, operational dependency and potential GxP impact.
Yes. Quality agreements can be developed or assessed for responsibility allocation, notification requirements, audit rights, records, systems, inspections, CAPA, change control and escalation.
Yes. Metrics can cover service performance, quality events, recurring errors, CAPAs, changes, audit findings, data quality, timeliness and risk escalation.
Yes. Support can include risk assessment, CAPA review, enhanced oversight, governance meetings, escalation, effectiveness review and controlled transition planning.
Yes. Risk assessments, document review, qualification interviews, remote audits, quality-agreement development and governance support can be delivered remotely or through a hybrid model.